JP2015522581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522581A5 JP2015522581A5 JP2015519155A JP2015519155A JP2015522581A5 JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5 JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015519155 A JP2015519155 A JP 2015519155A JP 2015522581 A5 JP2015522581 A5 JP 2015522581A5
- Authority
- JP
- Japan
- Prior art keywords
- hcmv
- membrane protein
- protein complex
- recombinant nucleic
- glycoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 72
- 108010052285 Membrane Proteins Proteins 0.000 claims description 36
- 102000018697 Membrane Proteins Human genes 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 102000003886 Glycoproteins Human genes 0.000 claims description 30
- 108090000288 Glycoproteins Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 241000710929 Alphavirus Species 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 6
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 4
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims description 4
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 4
- 101710144128 Non-structural protein 2 Proteins 0.000 claims description 4
- 101710144111 Non-structural protein 3 Proteins 0.000 claims description 4
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims description 4
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims description 4
- 102100031056 Serine protease 57 Human genes 0.000 claims description 4
- 101710197596 Serine protease 57 Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 230000037452 priming Effects 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668975P | 2012-07-06 | 2012-07-06 | |
| US61/668,975 | 2012-07-06 | ||
| US201361770257P | 2013-02-27 | 2013-02-27 | |
| US61/770,257 | 2013-02-27 | ||
| PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149178A Division JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149179A Division JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015522581A JP2015522581A (ja) | 2015-08-06 |
| JP2015522581A5 true JP2015522581A5 (enExample) | 2016-07-14 |
Family
ID=48783208
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519155A Pending JP2015522581A (ja) | 2012-07-06 | 2013-06-29 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149178A Pending JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149179A Pending JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017149178A Pending JP2017192399A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
| JP2017149179A Pending JP2017192400A (ja) | 2012-07-06 | 2017-08-01 | サイトメガロウイルスタンパク質の複合体 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9683022B2 (enExample) |
| EP (1) | EP2869843B1 (enExample) |
| JP (3) | JP2015522581A (enExample) |
| KR (1) | KR20150031322A (enExample) |
| CN (1) | CN104853771A (enExample) |
| AU (1) | AU2013286093B2 (enExample) |
| CA (1) | CA2878344A1 (enExample) |
| ES (1) | ES2753138T3 (enExample) |
| GB (1) | GB2513768B (enExample) |
| HK (1) | HK1210037A1 (enExample) |
| IL (1) | IL236261A0 (enExample) |
| IN (1) | IN2014KN02929A (enExample) |
| MX (2) | MX378747B (enExample) |
| RU (1) | RU2015103891A (enExample) |
| SG (1) | SG11201408328VA (enExample) |
| WO (1) | WO2014005959A1 (enExample) |
| ZA (1) | ZA201409364B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| AU2013293570B2 (en) | 2012-07-27 | 2019-05-23 | City Of Hope | An MVA vaccine for delivery of a UL128 complex and preventing CMV infection |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HRP20211015T1 (hr) * | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| US20170119874A1 (en) * | 2014-04-23 | 2017-05-04 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| EP3139953A1 (en) * | 2014-05-08 | 2017-03-15 | Pfizer Inc. | Means and methods for treating cmv |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| WO2017044895A2 (en) | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| MA46316A (fr) * | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2020515522A (ja) * | 2017-01-27 | 2020-05-28 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物 |
| LT3606942T (lt) | 2017-04-04 | 2025-10-10 | Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas | |
| CA3060019A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| WO2019020480A1 (en) * | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
| BR112020001052A2 (pt) | 2017-07-28 | 2020-09-08 | Janssen Vaccines & Prevention B.V. | métodos e composições para imunizações heterólogas com reprna |
| BR112020004747A2 (pt) * | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
| AU2019228551B2 (en) * | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| CN112638411B (zh) | 2018-05-04 | 2025-03-04 | 斯拜生物技术有限公司 | 疫苗组合物 |
| CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| JP7179872B2 (ja) | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| US11629172B2 (en) * | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| KR102837045B1 (ko) * | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4237085A1 (en) | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| MX2023009891A (es) * | 2021-02-24 | 2023-11-22 | Pfizer | Nuevas regiones susceptibles a modificarse por fármacos en el polipéptido de glucoproteína b del citomegalovirus humano y métodos de uso de las mismas. |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0452364B1 (en) | 1988-12-22 | 2002-05-22 | Genentech, Inc. | Method for preparing water soluble polypeptides |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| CA2088599A1 (en) | 1990-08-02 | 1992-02-03 | Carol A. Pachl | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
| WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
| CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011106607A2 (en) * | 2010-02-26 | 2011-09-01 | Juvaris Biotherapeutics, Inc. | Subunit vaccines for herpes viruses and methods of use |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
| WO2012034025A2 (en) | 2010-09-09 | 2012-03-15 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012106377A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| SG10201602456WA (en) * | 2011-08-31 | 2016-04-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 MX MX2018000675A patent/MX378747B/es unknown
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Withdrawn
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en not_active Ceased
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 HK HK15110880.5A patent/HK1210037A1/xx unknown
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522581A5 (enExample) | ||
| RU2015103891A (ru) | Комплексы белков цитомегаловируса | |
| JP7613685B2 (ja) | 新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物 | |
| RU2457250C2 (ru) | Способы и композиции для экспрессии антисмысловой вирусной рнк в клетках собаки | |
| KR20070086344A (ko) | 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터 | |
| NZ514132A (en) | Stable recombinant influenza viruses free of helper viruses | |
| JP2011182797A5 (enExample) | ||
| JP2021511318A (ja) | 組換えレプリコン系を使用する免疫応答の誘導および増強 | |
| JP2023551982A (ja) | マルチシストロン性ｒｎａワクチン及びその使用 | |
| JP2019530466A5 (enExample) | ||
| JP2010530245A5 (enExample) | ||
| CN103442731A (zh) | 表达系统 | |
| JPH09511143A (ja) | アルファーウイルスｃＤＮＡベクター | |
| JP2017522907A5 (enExample) | ||
| CA2406100A1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| CN118109489A (zh) | 编码新型冠状病毒的结构蛋白的核酸分子及其疫苗的应用 | |
| CN105396143B (zh) | 埃博拉病毒特异性的miRNA以及通过miRNA抑制埃博拉病毒的方法 | |
| JP2025169275A5 (enExample) | ||
| CN118086288B (zh) | 多顺反子的自放大rna及制备方法 | |
| JP6944692B2 (ja) | ボルナウイルスベクター及びその利用 | |
| CN107201370A (zh) | 一种dna分子与重组病毒及它们的制备方法和用途 | |
| Karlsson et al. | Live viral vectors: Semliki Forest virus | |
| Macnaughton et al. | HDV RNA replication: ancient relic or primer? | |
| Tizzano et al. | The cloning of the virus envelope glycoprotein F of canine distemper virus expressed in Pichia pastoris | |
| CN102286465B (zh) | 一种抑制口蹄疫病毒增殖的猪ifitm3基因及构建方法和应用 |